Form 4: UTHR Director's Equity Transactions

United Therapeutics Director Judy D. Olian reported the vesting of 1,190 restricted stock units into common stock and the grant of 1,310 new restricted stock units.

Summary

• Director Judy D. Olian acquired 1,190 shares of United Therapeutics Corporation common stock on July 25, 2025, through the vesting of restricted stock units.
• These 1,190 restricted stock units converted on a one-for-one basis into common stock.
• Following this transaction, Olian directly owns 6,845 shares of common stock.
• Olian also received an annual non-employee director award of 1,310 restricted stock units on July 24, 2025.
• These newly acquired restricted stock units are scheduled to vest on July 9, 2026.
• Olian now directly holds 1,310 restricted stock units.

Sentiment

Score: 7

Explanation: The filing details routine insider equity activity, which is a standard part of director compensation and aligns the director's interests with those of shareholders. It does not indicate any unexpected positive or negative developments for the company.

Positives

• Director Judy D. Olian received a new equity award of 1,310 restricted stock units, aligning her interests with shareholders.
• The vesting of 1,190 restricted stock units demonstrates the execution of the company's director compensation structure.

Future Outlook

The 1,310 restricted stock units granted to Director Judy D. Olian are scheduled to vest on July 9, 2026.

Industry Context

NA

Related Party Transactions

• Grant of 1,310 restricted stock units to Director Judy D. Olian as part of her annual non-employee director compensation.

Stakeholder Impact

• Shareholders benefit from the increased alignment of Director Judy D. Olian's interests with their own through her equity holdings.

Next Steps

• Vesting of 1,310 restricted stock units on July 9, 2026.

Key Dates

Recommendation

This Form 4 details routine equity compensation and vesting for a director, which is a standard part of corporate governance and aligns insider interests with shareholders. It does not contain information that would significantly alter the investment thesis for United Therapeutics Corporation, thus a 'hold' recommendation is appropriate.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Director Compensation, Restricted Stock Units, Equity Award